Alice

LenioBio announces appointment of new Chief Business Officer to Leadership Team

Retrieved on: 
Thursday, August 4, 2022
LinkedIn, Cosmetics, CEO, Technology, Goal, Lead, Alice, Rest, Protein, Small Business Saturday, Management, Fine chemical

DSSELDORF, Germany, Aug. 4, 2022 /PRNewswire/ -- LenioBio GmbH, the German life science biotech offering a disruptive protein manufacturing technology, today announced the appointment of Mr. Jasper Levink to its Leadership Team in the role of Chief Business Officer.

Key Points: 
  • DSSELDORF, Germany, Aug. 4, 2022 /PRNewswire/ -- LenioBio GmbH, the German life science biotech offering a disruptive protein manufacturing technology, today announced the appointment of Mr. Jasper Levink to its Leadership Team in the role of Chief Business Officer.
  • In his new role as Chief Business Officer, Mr. Levink will be responsible for driving LenioBio's business development and business strategy.
  • "We are thrilled that Jasper Levink has agreed to take this senior role at LenioBio," said CEO, Remberto Martis.
  • said Mr. Levink "I look forward to working with the rest of the leadership team to develop our business towards achieving these goals. "

LenioBio announces appointment of new Chief Business Officer to Leadership Team

Retrieved on: 
Thursday, August 4, 2022
LinkedIn, Cosmetics, CEO, Technology, Goal, Lead, Alice, Rest, Protein, Small Business Saturday, Management, Fine chemical

DSSELDORF, Germany, Aug. 4, 2022 /PRNewswire/ -- LenioBio GmbH, the German life science biotech offering a disruptive protein manufacturing technology, today announced the appointment of Mr. Jasper Levink to its Leadership Team in the role of Chief Business Officer.

Key Points: 
  • DSSELDORF, Germany, Aug. 4, 2022 /PRNewswire/ -- LenioBio GmbH, the German life science biotech offering a disruptive protein manufacturing technology, today announced the appointment of Mr. Jasper Levink to its Leadership Team in the role of Chief Business Officer.
  • In his new role as Chief Business Officer, Mr. Levink will be responsible for driving LenioBio's business development and business strategy.
  • "We are thrilled that Jasper Levink has agreed to take this senior role at LenioBio," said CEO, Remberto Martis.
  • said Mr. Levink "I look forward to working with the rest of the leadership team to develop our business towards achieving these goals. "

 Whole Health School of Medicine to become Alice L. Walton School of Medicine

Retrieved on: 
Thursday, June 30, 2022
Science, Other Science, Alternative Medicine, General Health, Health, Continuing, Education, Training, Medical education, Crystal Bridges Museum of American Art, School, Liaison Committee on Medical Education, University of Pittsburgh School of Medicine, Student, Education, Crystal, Foot, Curriculum, Humanities, Faculty, AIA, Partnership, Cleveland Clinic, Learning, Accreditation, Polk Stanley Wilcox Architects, Health, Quality of life, Outline of health sciences, OSD, Ecology, Physician, Mental health, Coffeehouse, Recreation, Multimedia, Alice, Pharmaceutical industry, Medicine, Management, Road, Medicine

*

Key Points: 
  • *
    The Alice L. Walton School of Medicine Board of Directors held their first meeting and voted unanimously to approve the name change on June 29.
  • Reflective of this commitment and vision, the School will now bear its founders name: Alice L. Walton School of Medicine.
  • We are honored to add Alice L. Walton to the School of Medicines name, highlighting our founders dedication to reimagining medical education, said Walter Harris, Chief Operating Officer for Alice L. Walton School of Medicine.
  • Arkansas-based firm Polk Stanley Wilcox has been selected as the lead architects for the Alice L. Walton School of Medicine building project.

LenioBio reaches industrial-scale with its high-yield eukaryotic platform for cell-free protein synthesis

Retrieved on: 
Wednesday, June 8, 2022
Achievement, Research, CFPS, LinkedIn, Thomas Jefferson National Accelerator Facility, Technology, EU, Protein folding, Adoption, Glycosylation, Industry, Alice, Protein, Fine chemical, Vaccine

This offers a significant step forward in eukaryotic protein expression.

Key Points: 
  • This offers a significant step forward in eukaryotic protein expression.
  • CFPS systems offer a number of benefits over cell-based protein alternatives, including shorter protein production time (hours vs. months), and the ability to produce proteins at levels usually toxic to living cells.
  • LenioBio will be exhibiting within the European Innovation Council Pavilion (Hall C, booth #1911) at the 2022 BIO International Convention, June 13-16.
  • LenioBio is a protein expression platform company committed to advancing transformative technology for the discovery, development, and large-scale production of proteins, unconstrained by the limitations of the cell.

LenioBio reaches industrial-scale with its high-yield eukaryotic platform for cell-free protein synthesis

Retrieved on: 
Wednesday, June 8, 2022
Achievement, Research, CFPS, LinkedIn, Thomas Jefferson National Accelerator Facility, Technology, EU, Protein folding, Adoption, Glycosylation, Industry, Alice, Protein, Fine chemical, Vaccine

This offers a significant step forward in eukaryotic protein expression.

Key Points: 
  • This offers a significant step forward in eukaryotic protein expression.
  • CFPS systems offer a number of benefits over cell-based protein alternatives, including shorter protein production time (hours vs. months), and the ability to produce proteins at levels usually toxic to living cells.
  • LenioBio will be exhibiting within the European Innovation Council Pavilion (Hall C, booth #1911) at the 2022 BIO International Convention, June 13-16.
  • LenioBio is a protein expression platform company committed to advancing transformative technology for the discovery, development, and large-scale production of proteins, unconstrained by the limitations of the cell.

Xcel Energy Announces Leadership Changes

Retrieved on: 
Monday, May 16, 2022
Nuclear, Energy, Utilities, Oil, Gas, Missouri Public Service Commission, Strategic planning, PG&E, Leadership, Multimedia, Federal Energy Regulatory Commission, NASDAQ, Puget Sound Energy, Foreign policy, El Paso Electric, Alice, Public utility, Industry, Carbon, Business system planning, Xcel Energy, XEL, Regulation, General counsel, PG, Twitter, Kenney, PSE, CEO, Renewable energy, Management, Facebook

Xcel Energy announced several key leadership changes designed to advance the companys groundbreaking commitment to lead the companys clean energy transition.

Key Points: 
  • Xcel Energy announced several key leadership changes designed to advance the companys groundbreaking commitment to lead the companys clean energy transition.
  • (Photo: Business Wire)
    Alice Jackson, current president of Xcel Energy Colorado, is appointed to senior vice president, System Strategy and chief planning officer, leading a new enterprise-wide System Planning organization.
  • Rodriguez will join Xcel Energy June 1, with current Xcel Energy Texas and New Mexico President David Hudson officially retiring July 1.
  • Xcel Energy (NASDAQ: XEL) provides the energy that powers millions of homes and businesses across eight Western and Midwestern states.

A breakthrough in biopharmaceutical protein production; LenioBio announces a new proprietary cell line devoid of plant glycans

Retrieved on: 
Monday, May 16, 2022
CFPS, Immortalised cell line, Enzyme, CSO, Multimedia, Xylose, EU, Cell, Plant, Technology, Alice, Tobacco, Glycosylation, LinkedIn, Protein, Fine chemical

LenioBio's proprietary ALiCE platform is derived from a tobacco BY-2 plant cell lysate.

Key Points: 
  • LenioBio's proprietary ALiCE platform is derived from a tobacco BY-2 plant cell lysate.
  • Plant-based expression systems are ideal biofactories for the production of many different protein classes for a multitude of applications.
  • In a step towards offering greater flexibility to their customers, LenioBio has generated a BY-2 knockout cell line lacking those enzymes responsible for plant-specific fucose and xylose glycosylation.
  • The resulting lysate devoid of plant glycans, opens the door to a new line of ALiCE products offering the potential for customizable protein glycosylation.

A breakthrough in biopharmaceutical protein production; LenioBio announces a new proprietary cell line devoid of plant glycans

Retrieved on: 
Monday, May 16, 2022
CFPS, Tobacco, Alice, Xylose, EU, Plant, Glycosylation, LinkedIn, Protein, Enzyme, Immortalised cell line, CSO, Technology, Cell, Fine chemical

LenioBio's proprietary ALiCE platform is derived from a tobacco BY-2 plant cell lysate.

Key Points: 
  • LenioBio's proprietary ALiCE platform is derived from a tobacco BY-2 plant cell lysate.
  • Plant-based expression systems are ideal biofactories for the production of many different protein classes for a multitude of applications.
  • However, differences in the way plant cells and the cells of other organisms perform the important post-translational protein glycosylation step can limit the uses of some plant CFPS-produced proteins.
  • The resulting lysate devoid of plant glycans, opens the door to a new line of ALiCE products offering the potential for customizable protein glycosylation.

Emma Willard School Launches Record-Breaking $175 Million Capital Campaign

Retrieved on: 
Friday, May 13, 2022
Linda, Education, History, School for Creative and Performing Arts, Family, Leadership, Multimedia, Woman, Lefort, Parent, Campaign, School, Director, Board of Trustees of the University of Oregon, Learning, Alice, Trustee, Life, Character, Performing arts, Student, Board, Habit, Emma Willard School, Faculty, Empowerment, Love, Intelligence, Pharmaceutical industry, Medicine, Tutoring, Advancement

TROY, N.Y., May 13, 2022 /PRNewswire/ -- Emma Willard School today announced the public launch of a $175 million capital campaign that will support and strengthen the school's commitment to girls' education. Infinite Horizon: The Campaign for Emma Willard School, with $118,778,653 already committed toward the funding priorities of the campaign, is poised to achieve the largest known philanthropic investment ever for a girls' secondary school.

Key Points: 
  • TROY, N.Y., May 13, 2022 /PRNewswire/ -- Emma Willard School today announced the public launch of a $175 million capital campaign that will support and strengthen the school's commitment to girls' education.
  • Infinite Horizon: The Campaign for Emma Willard School, with $118,778,653 already committed toward the funding priorities of the campaign, is poised to achieve the largest known philanthropic investment ever for a girls' secondary school.
  • Emma Hart Willard was a trailblazer in the empowerment and education of young women, and this historic capital campaign seeks to honor and extend her legacy.
  • "Infinite Horizon: The Campaign for Emma Willard School will extend the bold vision of our founder.

Research Antibodies Market - Global Forecasts from 2022 to 2027 - ResearchAndMarkets.com

Retrieved on: 
Friday, April 29, 2022
Genetics, Science, Health, Research, Antibody, First Nations in Ontario, Emergent, Protein, Intention, Foundation, USD, Vaccine, Roche, Geriatrics, National Institute, Emergent BioSolutions, Research, Death, UN, B cell, COVID-19, Cell, Huntington's disease, Impact of the COVID-19 pandemic, Cancer, Growth, Martek Biosciences Corporation, Abcam, National Institutes of Health, Washington University School of Medicine, Immunohistochemistry, Buffer, Biomarker, Therapy, Proteomics, Multiple sclerosis, Parkinson's disease, CAGR, United Nations, Precision medicine, Alice, Foundation for Innovative New Diagnostics, Market, Bioreactor, Neurodegeneration, Genomics, NIH, Capital, TB, GlaxoSmithKline, Fine chemical, Pharmaceutical industry

The "Global Research Antibodies Market - Forecasts from 2022 to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Research Antibodies Market - Forecasts from 2022 to 2027" report has been added to ResearchAndMarkets.com's offering.
  • The Research Antibodies market was valued at US$3.581 billion in 2020 and is expected to grow at a CAGR of 7.00% over the forecast period to reach a total market size of US$5.751 billion by 2027.
  • Powered by the increasing demand for tailored medicine and structure-based drug design, the global market for research antibodies is expected to grow rapidly over the next few years.
  • Research and development activities to develop novel vaccines and treatments have prompted a substantial increase in the demand for research antibodies.